Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...

The FDA informed Intercept that it is unable to approve the sNDA in its current form, consistent with the outcome of the Gastrointestinal Drugs Advisory Committee (GIDAC) meeting in September 2024. In ...

PharmaTher Holdings Ltd. (the "Company” or "PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced that the Company requested a post-complete letter clarification ...

This study introduces a novel lignin-based hydrogel with controlled release and enhanced mechanical strength, leveraging ...

The US FDA has cleared an investigational new drug (IND) application for HG202, by HuidaGene Therapeutics. This drug is the ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

The path from a scientist’s initial idea to a new medicine that can save lives is a complex and often lengthy process. It ...

Jump in fees for new drug applications expected An industry expert, who works in one of the top pharma companies of India, ...

must submit an NDS within 12 months of filing a New Drug Application (NDA) in the US. This requirement is established by ...

While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.

Medical experts who’ve studied the experimental treatment program, however, say there’s no evidence to support Trump’s claims ...